Mutation of a potassium channel-related gene in progressive myoclonic epilepsy

Patrick Van Bogaert1, Regis Azizieh, Julie Désir

  • 1Department of Pediatric Neurology, Université Libre de Bruxelles, Hôpital Erasme, Brussels, Belgium. pvanboga@ulb.ac.be

Annals of Neurology
|April 25, 2007
PubMed
Abstract

Insights

A novel mutation in the KCTD7 gene causes a severe form of progressive myoclonic epilepsy (PME) in a Moroccan family. This autosomal recessive disorder is linked to a new locus on chromosome 7q11.2.

Area of Science:

  • Genetics
  • Neurology
  • Molecular Biology

Background:

  • Progressive myoclonic epilepsy (PME) is a group of rare neurological disorders characterized by seizures, myoclonus, and progressive neurological decline.
  • Autosomal recessive inheritance patterns are observed in some forms of PME, suggesting a genetic basis.

Purpose of the Study:

  • To investigate a Moroccan family with suspected autosomal recessive PME.
  • To identify the specific gene responsible for PME in this consanguineous family.

Main Methods:

  • Clinical evaluation and electroencephalogram (EEG) and magnetic resonance imaging (MRI) of affected individuals.
  • Exclusion of known PME causes, followed by homozygosity mapping using microsatellite markers and SNP arrays.
  • Candidate gene analysis within the identified linkage region on chromosome 7q11.2.

Main Results:

  • A novel locus for PME was identified on chromosome 7q11.2.
  • A C-to-T mutation in exon 2 of the KCTD7 gene (R99X) was found in affected family members.
  • The mutation occurred in a highly conserved region of the KCTD7 protein, leading to a premature stop codon.

Conclusions:

  • The identified KCTD7 mutation is the likely cause of PME in this family, inherited in an autosomal recessive manner.
  • Neurodegeneration severity correlated with epilepsy refractoriness.
  • This study establishes a new genetic locus and gene for progressive myoclonic epilepsy.

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Voltage-gated Ion Channels01:26

Voltage-gated Ion Channels

Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
Voltage-gated Ion Channels01:26

Voltage-gated Ion Channels

Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Mutations01:39

Mutations

Overview
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...